Island Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir

MT Newswires Live

04/27

Island Pharmaceuticals' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.

It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.

It worked alongside Todd Strategy Group and MC2 to advance industry engagement initiatives in the US during the March quarter.

Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.

Its shares were up 1% in recent trading on Monday.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/hant/news/2630351272"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630351272\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630351272?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 13:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630351272","market":"nz","top_or_hot":-1,"title":"Island Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ILA.AU\">Island Pharmaceuticals</a>' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.</p><p>It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.</p><p>It worked alongside Todd <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Group and MC2 to advance industry engagement initiatives in the US during the March quarter.</p><p>Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.</p><p>Its shares were up 1% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Island Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIsland Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2026-04-27 13:07</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ILA.AU\">Island Pharmaceuticals</a>' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.</p><p>It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.</p><p>It worked alongside Todd <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Group and MC2 to advance industry engagement initiatives in the US during the March quarter.</p><p>Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.</p><p>Its shares were up 1% in recent trading on Monday.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"製藥","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2630351272","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630351272","pubTimestamp":1777266438,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Island Pharmaceuticals' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phas","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","ILA.AU":"ISLAND PHARMACEUTICALS LTD"},"translate_title":"Island Pharmaceuticals与USAMRIID合作推进加利德西韦的临床开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILA.AU":1},"content_text":"Island Pharmaceuticals' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.It worked alongside Todd Strategy Group and MC2 to advance industry engagement initiatives in the US during the March quarter.Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.Its shares were up 1% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}